Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

Celcuity shares skyrocketed to an all-time high when the biotech reported positive results from a Phase 3 trial of its ...

A phase 3 trial of Celcuity’s breast cancer combination has hit its primary endpoints, blasting past the biotech’s bar for ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Celcuity Inc. (NASDAQ:CELC) saw its stock soar by more than 100% on Monday following the release of groundbreaking Phase 3 ...

Celcuity Inc. (CELC) stock surged about 221% on Monday morning after the company announced that its experimental combination ...

But for those taking fulvestrant and a placebo, cancer returned in an average of five months, the study found. Side effects were more common in the group taking the new drug combo, however.

The Food and Drug Administration (FDA) has approved Truqap ™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal ...

The addition of dalpiciclib to fulvestrant appeared effective and safe for certain patients with advanced breast cancer, according to randomized phase 3 study results presented during the virtual ...

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...

Correspondence Anastrozole and Fulvestrant in Metastatic Breast Cancer Published October 25, 2012 N Engl J Med 2012;367: 1662 - 1664 DOI: 10.1056/NEJMc1210463 ...

For fulvestrant to work well, the cells must also be responsive to estrogen, and producing the estrogen receptor ER-alpha. ER-alpha's importance to fulvestrant's anti-estrogenic action had been ...